@UChicagoMed Comprehensive Cancer Center designated by @theNCI for 50 yrs. #NothingWillStopUs #WeAreNCIDesignated uchicagocancer.bsky.social
Joined June 2010
- Tweets 15,062
- Following 1,583
- Followers 10,153
- Likes 9,187
4,549 Photos and videos
Pinned Tweet
29 Jul 2025
The @USNEWS Best Hospitals national rankings are in and @UCCCC's cancer program is #1 in Illinois for the 3rd consecutive year and #12 in the country again. We are proud of this distinction and honored to serve our patients with top-quality cancer care. #WeAreNCIDesignated
3
8
26
3,128
UChicagoCancerCenter retweeted
Dr. Behera of @UCCancerCenter summarizes what he just discussed on #ASCO26 lung cancer updates at the third annual review meeting.
Exciting updates.
#HealthcareUnfiltered
1
2
7
890
UChicagoCancerCenter retweeted
A frequent guest on #HealthcareUnfiltered podcast - @DanielOlsonMD of @UCCancerCenter takes the podium for melanoma updates from #ASCO26. #HealthcareUnfiltered
2
6
347
UChicagoCancerCenter retweeted
Did management of DLBCL change since #ASCO26?
Dr. Rojek at @UCCancerCenter just delivered an excellent talk at the annual meeting review, and shares some thoughts with #HealthcareUnfiltered
1
2
5
410
.@AACR interviewed Long Chi Nguyen, PhD, MD about his research into how BACH1 drives hypoxia-induced stem-like transition states and immune evasion in breast cancer. #AACR26 vimeo.com/1185211822?fe=sh&f…
5
601
Alex Pearson, MD, PhD, and colleagues reports that prompt direct ambient AI improves quality of summaries as compared to manual or ambient AI generated documents during head and neck tumor board discussions. @lab_pearson @Annals_Oncology @UChicagoOHNS
ow.ly/fvBc50Zb8sw
6
8
364
UChicagoCancerCenter retweeted
Jun 11
🧬 Brenetafusp in advanced melanoma: ORR may be modest, but the DCR tells a different story. @DanielOlsonMD, of @UChicagoMed, discusses updated phase 1 data from #ASCO26 @ASCO:
✅ DCR: 52%–67% depending on dose
✅ Median OS: 14.3 months
✅ CRS attenuates with step-up dosing
Phase 3 PRISM-MEL trial now underway combining brenetafusp nivolumab in the frontline setting 👀
#melsm #oncology hubs.ly/Q04l7LLn0
1
2
437
UChicagoCancerCenter retweeted
congrats to @Anand_88_Patel who is a co-author on a new analysis looking at outcomes of patients with hairy cell leukemia!
pubmed.ncbi.nlm.nih.gov/4228…
1
4
212
RT @UChicagoMed: Important Notice: Expect Hyde Park-area traffic delays June 15-21.
If you are visiting our Hyde Park medical campus, Cott…
1
Meet Olufunmilayo “Funmi” Olopade, MD (@folopade), Director of the Centers for Clinical Cancer Genetics and Innovation in Global Health, and a world-renowned expert in cancer risk assessment and individualized treatment for #breastcancer. ow.ly/7rIc50Z3nkA #FollowFriday
2
7
269
UChicagoCancerCenter retweeted
Jun 11
🧠🔬 AI is generating excitement across oncology—but where can it realistically add value in breast pathology today?
📺 In the video below, @fredhow of @UCCancerCenter discusses the current limitations of AI, opportunities for integration into pathology workflows, and what still needs to happen for its broader adoption.
WATCH NOW ⬇️ #bcsm #AI #oncology onclive.com/view/dr-howard-o…
1
3
373
UChicagoCancerCenter retweeted
About to get started @UCCancerCenter third annual #ASCO26 update - #HealthcareUnfiltered podcast proud partner.
Lots of updates from an exciting meeting app day long.
2
1
5
406
UChicagoCancerCenter retweeted
A new study published in @gynoncjnls shows reduced-dose lenvatinib was associated with higher response rates & improved tolerability in patients with recurrent endometrial cancer, including those with platinum-resistant & high-grade disease.
Read: bit.ly/3Qk57OP
2
2
283
UChicagoCancerCenter retweeted
Happening tomorrow: #HealthcareUnfiltered podcast and @UCCancerCenter collaboration on the third annual ASCO review, where data from #ASCO26 are shared broadly.
Follow live coverage, interviews, discussions, streaming everywhere.
Thank you to all faculty & attendees.
4
7
433
@UCCancerCenter faculty and trainees showcased at #ASCO2026, the world's largest oncology conference, with presentations spanning from practice-changing clinical trials, genetic testing, palliative care, AI-driven drug discovery, and cancer prevention.
ow.ly/srga50ZaAhY
4
6
258
UChicagoCancerCenter retweeted
This week's #HealthcareUnfiltered podcast with @DanielOlsonMD of @UCCancerCenter was all about TILs, with a focus on melanoma.
Lots to learn about this modality of cellular therapy, its challenges, applications, and future directions.
Check it out: podcasts.apple.com/us/podcas…
3
6
675
Ardaman Shergill, MD, and colleagues report that early-onset appendiceal adenocarcinoma may be a distinct subtype, highlighting the need for larger prospective studies to guide clinical management. @ArdamanShergil1 @AnnSurgOncol @uchicagosurgery
ow.ly/1Zt650Zayvv
1
8
13
1,259
Nearly 159,000 people in the United States will be diagnosed with colorectal cancer this year. Read about the prevention, screening, and treatment options for #ColorectalCancer: brnw.ch/21x3fvV
1
2
777
Dr. Soni Smith discusses the implications of data for tafasitamab plus lenalidomide/R-CHOP in high-risk diffuse large B-cell #lymphoma. WATCH: onclive.com/view/dr-smith-on… @SoniSmithMD @UChicagoHemOnc @OncLive #DLBCL #ASCO26
1
4
231
Slideflow Labs, an AI pathology company spun out of a @UChicago research lab, is revolutionizing cancer care through its advanced biomarker development and deployment directly into hospital settings. @lab_pearson @UChicagoPath @UChicagoMed @UChicagoHemOnc
ow.ly/SN3a50Za57e
1
3
10
546
Dr. Aditya Juloori took part in a roundtable discussion of difficult treatment decisions in NSCLC. See the video: oncologynewscentral.com/vide… @ajuloorimd @OncNewsCentral #lcsm
3
1
7
817